Evonik, EUROAPI, Porton announce technological expansions The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe
The FDA has studied a possible link between some grain-free diets and canine heart disease, though research continues
Confirm on the brands own site which products it dispenses and how fulfillment works before enrolling
Patients must attend follow-up appointments as prescribed